Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Puig

Showing results (41-50 of 121) with videos related to

Pageof 13
Sort By:
Cancer Biology & Therapy|November 15, 2018
Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutisNina Anika Richarz, Luis Puig, Noelia Pérez, et al.
The American Journal of Dermatopathology|June 8, 2010
Grover disease: a reappraisal of histopathological diagnostic criteria in 120 casesMaría-Teresa Fernández-Figueras, Luis Puig, Pablo Cannata, et al.
The Journal of Clinical and Aesthetic Dermatology|February 15, 2021
Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A <i>Post-hoc</i> Analysis from a Long-term Clinical StudyLuis Puig, Baojin Zhu, Russel Burge, et al.
Dermatology and Therapy|October 22, 2022
A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysisApril W Armstrong, Ahmed M Soliman, Keith A Betts, et al.
Dermatology and Therapy|March 31, 2021
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysisApril W Armstrong, Ahmed M Soliman, Keith A Betts, et al.
Advances in Therapy|July 17, 2025
Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023Luis Puig, Philipp Sewerin, Christopher Schuster, et al.
Acta Dermato-Venereologica|September 14, 2017
Dystrophic Calcification in a Patient with Primary Localized Cutaneous Nodular Amyloidosis: An Uncommon Ultrasound FindingSergi Planas-Ciudad, Esther Roé Crespo, Juan Francisco Mir-Bonafé, et al.
The Journal of Dermatological Treatment|October 16, 2019
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2Luis Puig, Jashin J Wu, Melinda J Gooderham, et al.
Dermatology and Therapy|December 4, 2021
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-AnalysisApril W Armstrong, Ahmed M Soliman, Keith A Betts, et al.
Dermatology and Therapy|May 10, 2024
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) StudyAndreas Pinter, Ahmed M Soliman, Irina Pivneva, et al.
Pageof 13

Showing results (41-50 of 121) with videos related to

Sort By:
Pageof 13
Cancer Biology & Therapy|November 15, 2018
Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutisNina Anika Richarz, Luis Puig, Noelia Pérez, et al.
The American Journal of Dermatopathology|June 8, 2010
Grover disease: a reappraisal of histopathological diagnostic criteria in 120 casesMaría-Teresa Fernández-Figueras, Luis Puig, Pablo Cannata, et al.
The Journal of Clinical and Aesthetic Dermatology|February 15, 2021
Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A <i>Post-hoc</i> Analysis from a Long-term Clinical StudyLuis Puig, Baojin Zhu, Russel Burge, et al.
Dermatology and Therapy|October 22, 2022
A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysisApril W Armstrong, Ahmed M Soliman, Keith A Betts, et al.
Dermatology and Therapy|March 31, 2021
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysisApril W Armstrong, Ahmed M Soliman, Keith A Betts, et al.
Advances in Therapy|July 17, 2025
Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023Luis Puig, Philipp Sewerin, Christopher Schuster, et al.
Acta Dermato-Venereologica|September 14, 2017
Dystrophic Calcification in a Patient with Primary Localized Cutaneous Nodular Amyloidosis: An Uncommon Ultrasound FindingSergi Planas-Ciudad, Esther Roé Crespo, Juan Francisco Mir-Bonafé, et al.
The Journal of Dermatological Treatment|October 16, 2019
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2Luis Puig, Jashin J Wu, Melinda J Gooderham, et al.
Dermatology and Therapy|December 4, 2021
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-AnalysisApril W Armstrong, Ahmed M Soliman, Keith A Betts, et al.
Dermatology and Therapy|May 10, 2024
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) StudyAndreas Pinter, Ahmed M Soliman, Irina Pivneva, et al.
Pageof 13